These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 17065619)

  • 1. Pharmacokinetic considerations and efficacy of levofloxacin in an inhalational anthrax (postexposure) rhesus monkey model.
    Kao LM; Bush K; Barnewall R; Estep J; Thalacker FW; Olson PH; Drusano GL; Minton N; Chien S; Hemeryck A; Kelley MF
    Antimicrob Agents Chemother; 2006 Nov; 50(11):3535-42. PubMed ID: 17065619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effective antimicrobial regimens for use in humans for therapy of Bacillus anthracis infections and postexposure prophylaxis.
    Deziel MR; Heine H; Louie A; Kao M; Byrne WR; Basset J; Miller L; Bush K; Kelly M; Drusano GL
    Antimicrob Agents Chemother; 2005 Dec; 49(12):5099-106. PubMed ID: 16304178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Post-exposure therapy of inhalational anthrax in the common marmoset.
    Nelson M; Stagg AJ; Stevens DJ; Brown MA; Pearce PC; Simpson AJ; Lever MS
    Int J Antimicrob Agents; 2011 Jul; 38(1):60-4. PubMed ID: 21530184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determination of antibiotic efficacy against Bacillus anthracis in a mouse aerosol challenge model.
    Heine HS; Bassett J; Miller L; Hartings JM; Ivins BE; Pitt ML; Fritz D; Norris SL; Byrne WR
    Antimicrob Agents Chemother; 2007 Apr; 51(4):1373-9. PubMed ID: 17296745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aerosolized Bacillus anthracis infection in New Zealand white rabbits: natural history and intravenous levofloxacin treatment.
    Yee SB; Hatkin JM; Dyer DN; Orr SA; Pitt ML
    Comp Med; 2010 Dec; 60(6):461-8. PubMed ID: 21262133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacometrics-based dose selection of levofloxacin as a treatment for postexposure inhalational anthrax in children.
    Li F; Nandy P; Chien S; Noel GJ; Tornoe CW
    Antimicrob Agents Chemother; 2010 Jan; 54(1):375-9. PubMed ID: 19858256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of oritavancin in a murine model of Bacillus anthracis spore inhalation anthrax.
    Heine HS; Bassett J; Miller L; Bassett A; Ivins BE; Lehoux D; Arhin FF; Parr TR; Moeck G
    Antimicrob Agents Chemother; 2008 Sep; 52(9):3350-7. PubMed ID: 18606841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A short course of antibiotic treatment is effective in preventing death from experimental inhalational anthrax after discontinuing antibiotics.
    Vietri NJ; Purcell BK; Tobery SA; Rasmussen SL; Leffel EK; Twenhafel NA; Ivins BE; Kellogg MD; Webster WM; Wright ME; Friedlander AM
    J Infect Dis; 2009 Feb; 199(3):336-41. PubMed ID: 19099484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short-course postexposure antibiotic prophylaxis combined with vaccination protects against experimental inhalational anthrax.
    Vietri NJ; Purcell BK; Lawler JV; Leffel EK; Rico P; Gamble CS; Twenhafel NA; Ivins BE; Heine HS; Sheeler R; Wright ME; Friedlander AM
    Proc Natl Acad Sci U S A; 2006 May; 103(20):7813-6. PubMed ID: 16672361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathology of inhalation anthrax in cynomolgus monkeys (Macaca fascicularis).
    Vasconcelos D; Barnewall R; Babin M; Hunt R; Estep J; Nielsen C; Carnes R; Carney J
    Lab Invest; 2003 Aug; 83(8):1201-9. PubMed ID: 12920249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics, metabolism, excretion and plasma protein binding of 14C-levofloxacin after a single oral administration in the Rhesus monkey.
    Hemeryck A; Mamidi RN; Bottacini M; Macpherson D; Kao M; Kelley MF
    Xenobiotica; 2006 Jul; 36(7):597-613. PubMed ID: 16864506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Fluorocycline TP-271 Is Efficacious in Models of Aerosolized Bacillus anthracis Infection in BALB/c Mice and Cynomolgus Macaques.
    Grossman TH; Anderson MS; Drabek L; Gooldy M; Heine HS; Henning LN; Lin W; Newman JV; Nevarez R; Siefkas-Patterson K; Radcliff AK; Sutcliffe JA
    Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28784679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. US Food and Drug Administration approval of ciprofloxacin hydrochloride for management of postexposure inhalational anthrax.
    Meyerhoff A; Albrecht R; Meyer JM; Dionne P; Higgins K; Murphy D
    Clin Infect Dis; 2004 Aug; 39(3):303-8. PubMed ID: 15306995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of Combination Drug Therapy for Treatment of Antibiotic-Resistant Inhalation Anthrax in a Murine Model.
    Heine HS; Shadomy SV; Boyer AE; Chuvala L; Riggins R; Kesterson A; Myrick J; Craig J; Candela MG; Barr JR; Hendricks K; Bower WA; Walke H; Drusano GL
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28696235
    [No Abstract]   [Full Text] [Related]  

  • 15. Pharmacokinetic-pharmacodynamic assessment of faropenem in a lethal murine Bacillus anthracis inhalation postexposure prophylaxis model.
    Gill SC; Rubino CM; Bassett J; Miller L; Ambrose PG; Bhavnani SM; Beaudry A; Li J; Stone KC; Critchley I; Janjic N; Heine HS
    Antimicrob Agents Chemother; 2010 May; 54(5):1678-83. PubMed ID: 20145081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid
    Lawrence WS; Peel JE; Slayden RA; Peterson JW; Baze WB; Hensel ME; Whorton EB; Beasley DWC; Cummings JE; Macias-Perez I
    Antimicrob Agents Chemother; 2024 Jul; 68(7):e0011224. PubMed ID: 38888319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic-pharmacodynamic analysis of fluoroquinolones against Bacillus anthracis.
    Kihira T; Sato J; Shibata T
    J Infect Chemother; 2004 Apr; 10(2):97-100. PubMed ID: 15160302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activity of dalbavancin against Bacillus anthracis in vitro and in a mouse inhalation anthrax model.
    Heine HS; Purcell BK; Bassett J; Miller L; Goldstein BP
    Antimicrob Agents Chemother; 2010 Mar; 54(3):991-6. PubMed ID: 20047912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Omadacycline is active
    Heine HS; Drusano G; Purcell BK; Anastasiou D; Tanaka SK; Serio AW
    Antimicrob Agents Chemother; 2024 Sep; 68(9):e0059524. PubMed ID: 39133023
    [No Abstract]   [Full Text] [Related]  

  • 20. Evaluation by Monte Carlo simulation of levofloxacin dosing for complicated urinary tract infections caused by Escherichia coli or Pseudomonas aeruginosa.
    Deguchi T; Seike K; Yasuda M; Matsumoto T
    J Infect Chemother; 2011 Oct; 17(5):726-30. PubMed ID: 21409530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.